期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 32, 期 3, 页码 225-242出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2022.2023129
关键词
Janus kinase; JAK3 subtype; JAK3 inhibitor; autoimmune disease; patent review
资金
- National Natural Science Foundation of China [81973338, 82104189]
This review provides an overview of the available patent literature on JAK-family inhibitors and the clinical activities of selective JAK3 inhibitors. Although no selective JAK3 inhibitors have been approved for clinical use, recent studies have shown the promising therapeutic potential of these inhibitors in inflammatory and autoimmune diseases.
Introduction Up to now, a total of eight Janus kinase (JAK) inhibitors have been approved for the treatment of autoimmune and myeloproliferative disease. The JAK family belongs to the non-receptor tyrosine kinase family, consisting of JAK1, JAK2, JAK3, and Tyk2. Among these four subtypes, only JAK3 is mainly expressed in hematopoietic tissue cells and is exclusively associated with the cytokines shared in the common gamma-chain receptor subunit. Due to its specific tissue distribution and functional characteristics that distinguish it from the other JAKs family subtypes, JAK3 is a promising target for the treatment of autoimmune disease. Areas covered This study aimed to provide a comprehensive review of the available patent literature on JAK-family inhibitors published from 2016 to the present. In addition, an overview of the clinical activities of selective JAK3 inhibitors in recent years was provided. Expert opinion To date, no selective JAK3 inhibitors have been approved for use in clinics. Over the last 5 years, an increasing number of studies on JAK3 inhibitors, particularly ritlecitinib by Pfizer, have demonstrated their promising therapeutic potential. In this review, recent studies reported that selective JAK3 inhibitors may offer valid, interesting, and promising therapeutic potential in inflammatory and autoimmune diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据